{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:02:04Z","timestamp":1791414124123,"version":"4.3.3"},"reference-count":21,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2001,3,1]],"date-time":"2001-03-01T00:00:00Z","timestamp":983404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2001,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Ro 63-9141 is a new member of the pyrrolidinone-3-ylidenemethyl cephem series of cephalosporins. Its antibacterial spectrum was evaluated against significant gram-positive and gram-negative pathogens in comparison with those of reference drugs, including cefotaxime, cefepime, meropenem, and ciprofloxacin. Ro 63-9141 showed high antibacterial in vitro activity against gram-positive bacteria except ampicillin-resistant enterococci, particularly vancomycin-resistant strains of\n                    <jats:italic>Enterococcus faecium<\/jats:italic>\n                    . Its MIC at which 90% of the isolates tested were inhibited (MIC\n                    <jats:sub>90<\/jats:sub>\n                    ) for methicillin-resistant\n                    <jats:italic>Staphylococcus aureus<\/jats:italic>\n                    (MRSA) was 4 \u03bcg\/ml. Ro 63-9141 was bactericidal against MRSA. Development of resistance to the new compound in MRSA was not observed. Ro 63-9141 was more potent than cefotaxime against penicillin-resistant\n                    <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n                    (MIC\n                    <jats:sub>90<\/jats:sub>\n                    = 2 \u03bcg\/ml). It was active against ceftazidime-susceptible strains of\n                    <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                    and against\n                    <jats:italic>Enterobacteriaceae<\/jats:italic>\n                    except\n                    <jats:italic>Proteus vulgaris<\/jats:italic>\n                    and some isolates producing extended-spectrum \u03b2-lactamases. The basis for the antibacterial spectrum of Ro 63-9141 lies in its affinity to essential penicillin-binding proteins, including PBP 2\u2032 of MRSA, and its stability towards \u03b2-lactamases. The in vivo findings were in accordance with the in vitro susceptibilities of the pathogens. These data suggest the potential utility of Ro 63-9141 for the therapy of infections caused by susceptible pathogens, including MRSA. Since insufficient solubility of Ro 63-9141 itself precludes parenteral administration in humans, a water-soluble prodrug, Ro 65-5788, is considered for development.\n                  <\/jats:p>","DOI":"10.1128\/aac.45.3.825-836.2001","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T06:06:42Z","timestamp":1027750002000},"page":"825-836","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":188,"title":["In Vitro and In Vivo Properties of Ro 63-9141, a Novel Broad-Spectrum Cephalosporin with Activity against Methicillin-Resistant Staphylococci"],"prefix":"10.1128","volume":"45","author":[{"given":"Paul","family":"Hebeisen","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Pharmaceutical Research, F. Hoffmann-La Roche Ltd.,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Heinze-Krauss","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Basilea Pharmaceutica,2 CH-4070 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Angehrn","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Pharmaceutical Research, F. Hoffmann-La Roche Ltd.,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hohl","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Pharmaceutical Research, F. Hoffmann-La Roche Ltd.,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm G. P.","family":"Page","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Basilea Pharmaceutica,2 CH-4070 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf L.","family":"Then","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Pharmaceutical Research, F. Hoffmann-La Roche Ltd.,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.2.462"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/clinids\/10.4.752","article-title":"Mechanism of inhibition of chromosomal \u03b2-lactamases by third-generation cephalosporins.","volume":"10","author":"Charnas R. L.","year":"1988","unstructured":"Charnas R. L. Then R. L. Mechanism of inhibition of chromosomal \u03b2-lactamases by third-generation cephalosporins. Rev. Infect. Dis. 10 1988 752 760","journal-title":"Rev. Infect. Dis."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.6.4.428"},{"key":"e_1_3_2_5_2","unstructured":"Finney\n              D. J.\n          Statistical method in biological assay\n          3rd ed.\n          1978\n          Charles Griffin & Co. Ltd.\n          London United Kingdom"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1086\/313710","article-title":"Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from SENTRY Antimicrobial Surveillance Program, 1997 and 1998.","volume":"30","author":"Fluit A. C.","year":"2000","unstructured":"Fluit A. C. Jones M. E. Schmitz F.-J. Acar J. Gupta R. Verhoef J. the SENTRY Participants Group Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from SENTRY Antimicrobial Surveillance Program, 1997 and 1998. Clin. Infect. Dis. 30 2000 454 460","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"722","DOI":"10.7164\/antibiotics.51.722","article-title":"Discovery of MC-02,331, a new cephalosporin exhibiting potent activity against methicillin-resistant Staphylococcus aureus.","volume":"51","author":"Hecker S. J.","year":"1998","unstructured":"Hecker S. J. Cho I. S. Glinka T. Zhang Z. J. Price M. E. Lee V. J. Christensen B. G. Boggs A. Chamberland S. Malouin F. Parr T. R. Annamalaj T. Blais J. Bond E. L. Case L. Chan C. Crase J. Frith R. Griffith D. Harford L. Liu N. Ludwikow M. Mathias K. Rea D. Williams R. Discovery of MC-02,331, a new cephalosporin exhibiting potent activity against methicillin-resistant Staphylococcus aureus. J. Antibiot. 51 1998 722 734","journal-title":"J. Antibiot."},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1021\/jm950886v","article-title":"Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.","volume":"39","author":"Heinze-Krauss L.","year":"1996","unstructured":"Heinze-Krauss L. Angehrn P. Guerry P. Hebeisen P. Hubschwerlen C. Kompis I. Page M. G. P. Richter H. G. F. Runtz V. Stalder H. Weiss U. Wei C.-C. Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci. J. Med. Chem. 39 1996 1864 1871","journal-title":"J. Med. Chem."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.1.135"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.3.799"},{"key":"e_1_3_2_11_2","first-page":"136","article-title":"Resistenzentwicklung bei Staphylokokken and anderen grampositiven Erregern gegen\u00fcber Chemotherapeutika im mitteleurop\u00e4ischen Raum.","volume":"8","author":"Kresken M.","year":"1999","unstructured":"Kresken M. Hafner D. Witte W. Reinert R. R. Resistenzentwicklung bei Staphylokokken and anderen grampositiven Erregern gegen\u00fcber Chemotherapeutika im mitteleurop\u00e4ischen Raum. Chemother. J. 8 1999 136 145","journal-title":"Chemother. J."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/(SICI)1098-1128(199911)19:6<521::AID-MED4>3.0.CO;2-9","article-title":"Antibiotic resistance versus small molecules, the chemical evolution.","volume":"19","author":"Lee V. J.","year":"1999","unstructured":"Lee V. J. Hecker S. J. Antibiotic resistance versus small molecules, the chemical evolution. Med. Res. Rev. 19 1999 521 542","journal-title":"Med. Res. Rev."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.11.2943"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1128\/jcm.23.5.832-839.1986","article-title":"The role of \u03b2-lactamase in staphylococcal resistance to penicillinase-resistant penicillins and cephalosporins.","volume":"23","author":"McDougal C. K.","year":"1996","unstructured":"McDougal C. K. Thornsberry C. The role of \u03b2-lactamase in staphylococcal resistance to penicillinase-resistant penicillins and cephalosporins. J. Clin. Microbiol. 23 1996 832 839","journal-title":"J. Clin. Microbiol."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.3.489-495.2000"},{"key":"e_1_3_2_16_2","unstructured":"National Committee for Clinical Laboratory Standards\n          Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically\n          4th ed. Approved standard M7\u2013A4\n          1997\n          National Committee for Clinical Laboratory Standards\n          Wayne Pa"},{"key":"e_1_3_2_17_2","unstructured":"National Committee for Clinical Laboratory Standards\n          Methods for antimicrobial susceptibility testing of anaerobic bacteria\n          4th ed. Approved standard M11\u2013A4\n          1997\n          National Committee for Clinical Laboratory Standards\n          Wayne Pa"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1042\/bj2950295","article-title":"The kinetics of non-stoichiometric bursts of beta-lactam hydrolysis catalysed by class C beta-lactamases.","volume":"295","author":"Page M. G. P.","year":"1993","unstructured":"Page M. G. P. The kinetics of non-stoichiometric bursts of beta-lactam hydrolysis catalysed by class C beta-lactamases. Biochem. J. 295 1993 295 304","journal-title":"Biochem. J."},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/bmj.320.7229.213","article-title":"Bacteremia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis.","volume":"320","author":"Reacher M. H.","year":"2000","unstructured":"Reacher M. H. Shah A. Livermore D. M. Wale M. C. J. Graham C. Johnson A. P. Heine H. Monnickendam M. A. Barker K. F. James D. George R. C. Bacteremia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. Br. Med. J. 320 2000 213 216","journal-title":"Br. Med. J."},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1086\/313658","article-title":"Methicillin-resistant Staphylococcus aureus: the other emerging resistant gram-positive coccus among liver transplant recipients.","volume":"30","author":"Singh N.","year":"2000","unstructured":"Singh N. Paterson D. L. Chang F. Y. Gayowski T. Squier C. Wagener M. M. Marino I. R. Methicillin-resistant Staphylococcus aureus: the other emerging resistant gram-positive coccus among liver transplant recipients. Clin. Infect. Dis. 30 2000 322 327","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.4.910"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.1.124"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.45.3.825-836.2001","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.45.3.825-836.2001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T12:11:09Z","timestamp":1645445469000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.45.3.825-836.2001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,3]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,3]]}},"alternative-id":["10.1128\/AAC.45.3.825-836.2001"],"URL":"https:\/\/doi.org\/10.1128\/aac.45.3.825-836.2001","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,3]]},"assertion":[{"value":"2000-09-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-12-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-03-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}